IL-17 mediated inflammation promotes tumor growth and progression in the skin - PubMed (original) (raw)

IL-17 mediated inflammation promotes tumor growth and progression in the skin

Donggou He et al. PLoS One. 2012.

Abstract

The mechanism for inflammation associated tumor development is a central issue for tumor biology and immunology and remains to be fully elucidated. Although IL-17 is implicated in association with inflammation mediated carcinogenesis, mechanisms are largely elusive. In the current studies, we showed that IL-17 receptor-A gene deficient (IL-17R-/-) mice were resistant to chemical carcinogen-induced cutaneous carcinogenesis, a well-established inflammation associated tumor model in the skin. The deficiency in IL-17R increased the infiltration of CD8+ T cells whereas it inhibited the infiltration of CD11b+ myeloid cells and development of myeloid derived suppressor cells. Inflammation induced skin hyperplasia and production of pro-tumor inflammatory molecules were inhibited in IL-17R-/- mice. We found that pre-existing inflammation in the skin increased the susceptibility to tumor growth, which was associated with increased development of tumor specific IL-17 producing T cells. This inflammation induced susceptibility to tumor growth was abrogated in IL-17R-/- mice. Finally, neutralizing IL-17 in mice that had already developed chemical carcinogen induced skin tumors could inhibit inflammation mediated tumor progression at late stages. These results demonstrate that IL-17 mediated inflammation is an important mechanism for inflammation mediated promotion of tumor development. The study has major implications for targeting IL-17 in prevention and treatment of tumors.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. IL-17 receptor deficient mice are resistant to DMBA/TPA induced carcinogenesis.

Mice were treated once with DMBA and then with TPA twice a week, as described in the Materials and Methods. Tumor growth was observed every week. A). Tumor incidence. B). Tumor multiplicity. C). The number of tumors was analyzed statistically at the end of experiments (26 weeks). The bar graph shows the mean number of tumors per mouse +/−SEM, n = 10, ** p<0.01. Data are representative of two independent experiments.

Figure 2

Figure 2. IL-17 has opposing effects on the infiltration of CD11b+ macrophages and CD8+ T cells in DMBA/TPA treated skin.

Mice were treated with DMBA and TPA as described in figure 1 and skin tissues were harvested at the end of the experiment (26 weeks). A). Frozen tissue sections were stained with CD11b antibodies (brown) and counterstained with hematoxylin (blue, upper panels) or with anti-CD8 antibodies (green) and counterstained with a fluorescence dye DAPI (blue, lower panel). Photos were taken microscopically (20× objective). Numbers of positive cells were counted microscopically. Islets show the enlarged areas of circled squares with positive cells. Graphs show the mean number of positive cells per field +/− SEM, n = 10, * p<0.05, ** P<0.01. B). Gr-1 and CD11b double positive cells in spleens were stained with fluorescence labeled antibodies and positive cells were analyzed in a flow cytometer. The numbers in the right upper quadrant indicate the percent of positive cells in whole spleen cells. C). Statistical analysis of GR-1/CD11b+ (myeloid derived suppressor cells), CD19/B220+ (B cells), CD8+ and CD4+ T cells in spleens (mean +/− SEM, n = 8, ** P<0.01). Data are representative of two independent experiments.

Figure 3

Figure 3. The deficiency in IL-17 receptor inhibits TPA induced tumor promoting inflammation in the skin.

Mice were treated topically with TPA every other day for a total of three applications. Skin tissues were harvested 24 hours after the last treatment. A). Paraffin embedded tissue sections were stained with hematoxylin. Skin samples from naïve untreated mice served as controls. Dashed lines indicate the border between the epidermis and dermis. The thickness of epidermis was measured microscopically (n = 10). B). Frozen tissue sections were stained immunohistochemcially with antibodies. CD11b+ (monocytes/macrophages) and Gr-1+ (granulocytes) cells were counted microscopically (n = 6). C) Concentrations of cytokines in the skin lysates were measured by ELISA (n = 4). D). S100A8 and S100A9 proteins in the skin lysates were detected by Western blots using specific antibodies. E). Concentrations of PGE2 in the skin lysates were measured by a PGE2 EIA kit (n = 3). F). Expression levels of mRNA for chemokines and cytokines in the skin lysates were quantified by real time RT-PCR (n = 3). Data are representative of 2–3 independent experiments (mean +/− SEM, * P<0.05: ** P<0.01).

Figure 4

Figure 4. TPA induced promotion of tumor growth is abrogated in IL-17R-/- mice.

A). TPA induced inflammation enhances tumor growth. Wild type C57Bl/6 mice were treated epicutaneously with TPA or acetone (vehicle controls) every other day for a total of 5 applications. The mice were then inoculated subcutaneously with EG7 tumor cells. Tumor growth was monitored (n = 5). B). TPA induced inflammation increases tumor specific IL-17 producing cells. At the end of experiments, the draining lymph node lymphocytes were collected from EG7 tumor bearing mice that were treated with TPA or acetone. The cells stimulated with OVA pulsed BM-DC for 4 days. Concentrations of cytokines in supernatants were measured by ELISA (n = 4). Naïve T cells with OVA pulsed BM-DC (Naïve) and immune T cells with BM-DC without OVA (Neg) served as controls in the cultures. C). TPA induced tumor promotion is abrogated in IL-17R-/- mice. Wild type or IL-17R-/- were epicutaneously treated with TPA or acetone every other day for a total of 5 applications. The mice were then inoculated with EG7 tumor cells and tumor growth was monitored (n = 5). Data are representative of 2–3 independent experiments (mean +/− SEM, * P<0.05).

Figure 5

Figure 5. Neutralization of IL-17 inhibits the progression of tumors in DMBA/TPA induced cutaneous carcinogenesis.

Wild type C57Bl/6 mice were topically treated once with DMBA and then twice weekly with TPA. All mice developed cutaneous tumors at 12 weeks. The mice were divided (10 mice/group) and treated intravenously with adenovirus encoding GFP (Ad-GFP), IL-17R:Fc (Ad-IL-17R:Fc) or left untreated (Ctrl) at week 12 and 16. All mice were continuously treated with TPA twice a week throughout the experiments. The tumor growth was monitored weekly. Bar graph shows the mean tumor number per mouse +/− SEM at the end of experiments (* P<0.05). Data are representative of 2 independent experiments.

References

    1. Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting. Annual Review of Immunology. 2004;22:329–360. - PubMed
    1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137–1146. - PMC - PubMed
    1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715. - PubMed
    1. Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol. 2001;70:171–184. - PubMed
    1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology. 2011;29:235–271. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources